Form 4: Neogenomics Director Neil Gunn Acquires Shares in Recent Transaction

Director Neil Gunn recently acquired shares of Neogenomics Inc. common stock at a price of $7.755 per share.

Summary

• On May 5, 2025, Neil Gunn, a director of Neogenomics Inc., purchased 4,510.31 shares of common stock at $7.755 per share.
• Following the transaction, Gunn directly owns 15,846.31 shares of Neogenomics Inc.
• Gunn also holds derivative securities, including stock options and restricted stock units, representing the right to buy or receive additional shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock purchase. While insider buying can be seen as a positive signal, it's a single transaction and doesn't provide strong evidence of a bullish outlook.

Positives

• The director's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies and are regulated to prevent illegal insider trading.
• The size and frequency of insider transactions are company-specific and depend on factors such as compensation structure and individual investment strategies.
• Comparing Neil Gunn's transactions to those of other directors in similar-sized companies within the diagnostics industry could provide a benchmark for assessing the significance of this activity.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Neogenomics, Director, Share Acquisition, Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Insider Trading